There is a growing recognition of the effects of RSV among older adults, particularly those in long-term care facilities. Here’s my take on how preventing transmission can save millions in healthcare costs.
Vaccines are at the forefront of the national consciousness, and manufacturers of the highly effective COVID-19 vaccines have entered the race to find an effective RSV vaccine.
The potential availability of an effective RSV vaccine for older individuals is on the horizon, and with it comes numerous ways to address vaccine hesitancy in this patient population.
We are closer than ever to finding an effective RSV vaccine, but recent challenges may delay approval.